CSL Seeking: Novel Approaches for Genetic Medicine

Closed: No Longer Taking Submissions

Welcome to CSL’s Open Innovation Submission Portal

CSL is a leading global biotech company that develops and delivers innovative biotherapies that help people with life-threatening medical conditions live full lives. Innovation has been in CSL’s DNA for more than a century. CSL has the full spectrum of strengths from research and clinical development to manufacturing and commercialization across six therapeutic areas of expertise. Their strengths enable them to accurately identify, successfully develop, and dependably deliver innovations for patients.

At CSL they believe that for innovation to be fast tracked, they need to partner with the brightest minds in the sector. They know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines and they collaborate and work with external organizations that have unique technologies, assets and equipment, to address patients’ unmet needs around the globe.

If you have an idea related to new products, new technologies or new advancements relating to CSL’s areas of interest, please feel free to share it via the Submission Form. All submissions will be screened by yet2 and if successful, will be shared with CSL. Initial submissions should not include any confidential information.

Core interests for early stage partnering

Gene Editing

1. Improve large insertional editing efficiencies in vivo
2. Technologies / assays to improve genome editing safety
3. Large nucleic acid template delivery

Gene Expression

1. Tissue/cell-specific or controllable expression of Gene of Interest (GOI)
2. Genetic elements enhancing regulation of cells of the immune system
3. RNA/DNA vectors that achieve durable expression of GOI
4. RNA modifications (base modification, Cap, poly A-tail)

In vivo Gene Delivery

1. Nanoparticles (LNP or other) achieving:
   • Tissue-specific delivery (liver, blood, kidney, others)
   • Low reactogenicity with potential for re-dosing
2. Targeting moiety for immune cells
3. Novel route or device of administration

Areas not of interest

1. Oncology (including hematological malignancies)
2. Ex vivo cell therapy
3. Viral vectors

Click each linked title to submit your solution for each need.

Image by Freepik